(TLRY) Tilray - Ratings and Ratios
Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: US88688T1007
TLRY: Cannabis, Beverage Alcohol, Wellness Products
Tilray Brands, Inc. is a multifaceted lifestyle consumer products company that has evolved beyond its origins in medical cannabis to become a diversified player in the beverage alcohol, wellness, and distribution sectors. With a global presence spanning Canada, the United States, Europe, Australia, New Zealand, Latin America, and other international markets, the company has established a robust footprint in various industries.
The companys diversified portfolio encompasses a wide range of products, including medical and adult-use cannabis, pharmaceutical and wellness products, beverage alcohol, and hemp-based food products. Tilrays brands, such as Tilray, Aphria, Charlottes Web, and Manitoba Harvest, among others, cater to diverse customer segments, including retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, governments, and direct-to-consumer sales.
Notably, Tilray has expanded its reach through strategic brand acquisitions and partnerships, bolstering its presence in the beverage alcohol and wellness sectors. The companys product offerings under various brands, such as Montauk Brewing, Shock Top, and SweetWater Brewing, demonstrate its commitment to catering to different consumer preferences and trends.
Analyzing the
From a fundamental perspective, TLRYs Market Cap stands at $649.35M CAD, with a negative P/E ratio and a forward P/E of 1000, indicating high growth expectations. The RoE of -28.82% suggests that the company is currently unprofitable. Considering these factors, a forecast for TLRY would depend on its ability to navigate the competitive landscape, manage its diversified portfolio, and achieve profitability.
Based on the
Additional Sources for TLRY Stock
TLRY Stock Overview
Market Cap in USD | 470m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception |
TLRY Stock Ratings
Growth Rating | -84.2 |
Fundamental | -23.9 |
Dividend Rating | 0.0 |
Rel. Strength | -76.9 |
Analysts | - |
Fair Price Momentum | 0.27 CAD |
Fair Price DCF | - |
TLRY Dividends
No Dividends PaidTLRY Growth Ratios
Growth Correlation 3m | -94.1% |
Growth Correlation 12m | -93.7% |
Growth Correlation 5y | -95.3% |
CAGR 5y | -58.07% |
CAGR/Max DD 5y | -0.59 |
Sharpe Ratio 12m | -3.02 |
Alpha | -84.96 |
Beta | 0.534 |
Volatility | 73.18% |
Current Volume | 760.8k |
Average Volume 20d | 1037.6k |
As of May 10, 2025, the stock is trading at CAD 0.59 with a total of 760,767 shares traded.
Over the past week, the price has changed by -6.35%, over one month by -21.33%, over three months by -57.86% and over the past year by -78.23%.
Neither. Based on ValueRay Fundamental Analyses, Tilray is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -23.89 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TLRY as of May 2025 is 0.27. This means that TLRY is currently overvalued and has a potential downside of -54.24%.
Tilray has no consensus analysts rating.
According to ValueRays Forecast Model, TLRY Tilray will be worth about 0.3 in May 2026. The stock is currently trading at 0.59. This means that the stock has a potential downside of -50.85%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 2.2 | 266.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.3 | -50.8% |